Ara
Toplam kayıt 6, listelenen: 1-6
Racial Disparity in Tumor Microenvironment and Outcomes in Residual Breast Cancer after Neoadjuvant Chemotherapy
(Kanser Enstitüsü, 2023-06-12)
Black patients with residual estrogen receptor-positive (ER+) breast cancer after neoadjuvant chemotherapy (NAC) have inferior survival compared to white women resulting racial disparity in breast cancer survival. Differences ...
Akciğer Kanseri ve Sol Meme Radyoterapisinde Kardiyak Altyapı Marjlarının Oluşturulması ve Tedavi Planı Optimizasyonu
(Kanser Enstitüsü, 2023)
In thoracic irradiations, the coronary arteries (CA) are involuntarily exposed to radiation and subsequent cardiovascular toxicities may occur. To avoid this, the importance of accurately creating the safety margins (SM) ...
Meme Kanserinde, Il-1β ile Tetiklenen Epitelyal Mezenkimal Dönüşümde Hücre İskeleti Dinamiklerinin İncelenmesi
(Sağlık Bilimleri Enstitüsü, 2023-03)
The presence of interleukin (IL)-1β, a proinflammatory cytokine, has been demonstrated in the breast cancer microenvironment. IL-1β supports cell survival, proliferation, adhesion, invasion, and migration mechanisms. It ...
Bortezomib ve İmatinib'in Pankreas Kanserinde Olası Sinerjistik Etkisinin İncelenmesi
(Sağlık Bilimleri Enstitüsü, 2023-05-22)
The high mortality rate among pancreatic cancer patients underlines the importance of proper treatment. However, the traditional treatment strategies remain inadequate indicating that alternative therapy options need to ...
Systemıc Vh4-34-Encoded Antıbody Responses Agaınst Commensal Bacterıa in Patıents Wıth Systemıc Lupus Erythematosus
(Kanser Enstitüsü, 2023-09)
The germline immunoglobulin variable heavy chain 4–34 encoding B lymphocytes (known as VH4–34 or 9G4 B cells) are endowed with inherent self-reactivity due to the presence of a germline AVY motif in their framework region ...
Pankreas Kanserinde Nectin-2 Ekspresyonu ile Sitotoksik T Hücre Fonksiyonları Arasındaki İlişki
(Kanser Enstitüsü, 2023)
Checkpoint inhibitors such as anti-CTLA-4, anti-PD1 and anti-PDL-1 are used in the treatment of various cancers. However, they cannot be used in pancreatic cancer due to the lack of PDL-1 expression. Other checkpoint ...